A Study of SHR-A1811 in Subjects With Ovarian Cancer

NCT06828354 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: SHR-A1811
DRUG: Paclitaxel Injection
DRUG: Doxorubicin Hydrochloride Liposome Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Topotecan Hydrochloride for Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.